{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
aminosalicylic acid
to a specific field?
Status:
Investigational
Source:
NCT00884520: Early Phase 1 Interventional Completed Lung Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:SODIUM TRIMETAPHOSPHATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodium tripolyphosphate hexahydrate (sodium trimetaphosphate) is used in laundry detergent as a detergent "builder". It may also be used as a buffering agent. It has been shown that fluoride varnishes containing sodium trimetaphosphate reduce enamel demineralization. Sodium trimetaphosphate enhances the effect of 250 p.p.m. fluoride toothpaste against enamel demineralization in vitro. It also demonstrated significant antimicrobial activity, especially against S. mutans, and may be considered a potential alternative for new dental materials.
Status:
Investigational
Source:
NCT00915356: Phase 2 Interventional Completed Atrial Fibrillation
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
AZD1305, an antiarrhythmic agent, blocks the hERG potassium channel, the L-type calcium, and the Sodium channel protein Nav1.5. AZD1305 participated in clinical trials for the management of atrial fibrillation and Left ventricular dysfunction. The benefit-risk profile was judged as unfavorable and the AZD1305 development programme was discontinued.
Status:
Investigational
Source:
NCT02031679: Phase 2 Interventional Completed Chronic Idiopathic Urticaria
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
AZD-1981, developed by AstraZeneca, is a potent (binding IC50 of 4nM), fully reversible, functionally non-competitive antagonist of human CRTh2. It blocks agonist-induced human eosinophil CD11b expression, shape change (including in whole blood), and chemotaxis as well as an basophil shape change and Th2-cell chemotaxis at IC50's of 8.5-50nM. Potency is similar across species as is plasma protein binding (~97%). AZD-1981 is a weak (10s of μM) inhibitor in vitro of CYP2C9, OATP1B1 and UGT1A1 as well as an inducer of CYP3A4. AZD-1981 was well tolerated and no safety concerns were identified.There was no beneficial clinical effect of AZD-1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD-1981 has being discontinued for asthma and chronic obstructive pulmonary disease. AstraZeneca is collaborating with Johns Hopkins University for the development of AZD-1981 in the treatment of chronic idiopathic urticaria. It is in phase II clinicals studies for the treatment of Urticaria.
Status:
Investigational
Source:
NCT04251182: Phase 2 Interventional Completed Alzheimer Disease
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01291108: Phase 2 Interventional Completed Glaucoma, Open-Angle
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Simenepag (AGN-210676) is a a small molecule selective prostaglandin EP2 agonist with EC50 of 5 nM. Allergan was developing simenepag for the treatment of glaucoma and ocular hypertension.
Status:
Investigational
Source:
NCT01034631: Phase 1/Phase 2 Interventional Completed Renal Cell Carcinoma
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
BNC105P, a vascular disrupting agent, is a disodium phosphate ester prodrug of BNC105. BNC105P is a tubulin polymerization inhibitor that suppresses cancer cell proliferation. BNC105P participated in phase I/II trial for patients with metastatic renal cell carcinoma. Although the primary endpoint was not met in an unselected population, correlative studies suggested several biomarkers that warrant further prospective evaluation. Besides, BNC105P was involved in phase II clinical trial as second-line chemotherapy for advanced malignant pleural mesothelioma. The drug was safe and tolerable, but the sole response was insufficient to warrant further research as a single agent. In addition, BNC105P in combination with Ibrutinib was studied in phase I trials for patients with chronic lymphocytic leukemia to determine the preliminary assessment of the efficacy.
Status:
Investigational
Source:
NCT04249336: Phase 3 Interventional Completed Dentin Hypersensitivity
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00934089: Phase 2 Interventional Completed Glaucoma, Open-Angle
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Taprenepag isopropyl (also known as PF-04217329) a prodrug of CP-544326 (active acid metabolite), a potent and selective EP(2) receptor agonist. Taprenepag isopropyl was studied in a clinical trials phase II involving patients with primary open angle glaucoma. According to Pfizer’s pipelines in May 2011, the study was discontinued.
Status:
Investigational
Source:
NCT01471665: Phase 2 Interventional Completed Asthma
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Fiboflapon sodium (GSK2190915) is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. The compound was originally developed by Amira Pharmaceuticals. Fiboflapon sodium (GSK2190915) exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. GSK2190915 also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. Oral administration of Fiboflapon sodium (GSK2190915) (1 mg/kg) resulted in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with >90% inhibition for up to 12 h and an EC50 of approximately 7 nM. When rat lungs were challenged in vivo with calcium-ionophore, Fiboflapon sodium inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively. Fiboflapon sodium is in Phase-II for Asthma (Adjunctive treatment) in Poland, Ukraine, Bulgaria, USA, United Kingdom and Canada (PO).
